Download PDF
Dialyse aktuell 2018; 22(03): 118-121
DOI: 10.1055/a-0555-5070
Schwerpunkt | Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Chronische, nicht dialysepflichtige Niereninsuffizienz

Bluthochdrucktherapie
Alexander Reshetnik
Med. Klinik mit SP Nephrologie, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
08 May 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Patienten mit chronischer Niereninsuffizienz (CNI) haben ein hohes kardiovaskuläres Risiko. Gleichzeitig weist der arterielle Hypertonus eine hohe Prävalenz in diesem Kollektiv auf. Entsprechend der vorhandenen Evidenz profitieren die Patienten mit CNI von einer Blutdruckeinstellung. Insbesondere bei albuminurischen Patienten sollten RAAS-Blocker die Medikamente der ersten Wahl sein. Aufgrund des meist höheren Alters und vorhandener Komorbiditäten sind diese Patienten unter der antihypertensiven Therapie strenger hinsichtlich der Nebenwirkungen wie akutes Nierenversagen, Elektrolytstörungen, Orthostase und Synkopen zu überwachen.

 

  • Literatur

  • 1 Muntner P, Anderson A, Charleston J. et al. Chronic Renal Insufficiency Cohort Study Investigators. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010; 55: 441-451 doi:10.1053/j.ajkd.2009.09.014
    CrossrefPubMedGoogle Scholar
  • 2 Mann JF, Gerstein HC, Pogue J. et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636
    CrossrefPubMedGoogle Scholar
  • 3 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 07.11.2017 pii: S0735–1097(17)41519–1. doi:10.1016/j.jacc.2017.11.006 [Epub ahead of print]
    PubMedGoogle Scholar
  • 4 Mancia G, Fagard R, Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219 doi:10.1093/eurheartj/eht151
    CrossrefPubMedGoogle Scholar
  • 5 Kidney Disease Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 337-414
    CrossrefGoogle Scholar
  • 6 Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (Suppl. 01) S1-S290
    PubMedGoogle Scholar
  • 7 SPRINT Research Group. Wright Jr JT, Williamson JD, Whelton PK. et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373: 2103-2116 doi:10.1056/NEJMoa1511939
    CrossrefPubMedGoogle Scholar
  • 8 Cheung AK, Rahman M, Reboussin DM. SPRINT Resaerch Group. Effects of Intensive BP Control in CKD. J Am Soc Nephrol 2017; 28: 2812-2823 doi:10.1681/ASN.2017020148
    CrossrefPubMedGoogle Scholar
  • 9 Rule AD, Gussak HM, Pond GR. et al. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 2004; 43: 112-119
    CrossrefPubMedGoogle Scholar
  • 10 Anderson S, Meyer TW, Rennke HG. et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619 doi:10.1172/JCI112013
    CrossrefPubMedGoogle Scholar
  • 11 SPS3 Study Group. Benavente OR, Coffey CS, Conwit R. et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013; 382: 507-515 doi:10.1016/S0140–6736(13)60852–1
    CrossrefPubMedGoogle Scholar
  • 12 Hirsch S, Hirsch J, Bhatt U. et al. Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success. Am J Nephrol 2012; 36: 430-437 doi:10.1159/000343453
    CrossrefPubMedGoogle Scholar
  • 13 Ku E, Gassman J, Appel LJ. et al. BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol 2017; 28: 671-677 doi:10.1681/ASN.2016030326
    CrossrefPubMedGoogle Scholar
  • 14 Kovesdy CP, Alrifai A, Gosmanova EO. et al. Age and Outcomes Associated with BP in Patients with Incident CKD. Clin J Am Soc Nephrol 2016; 11: 821-831 doi:10.2215/CJN.08660815
    CrossrefPubMedGoogle Scholar
  • 15 Weiss JW, Peters D, Yang X. et al. Systolic BP and Mortality in Older Adults with CKD. Clin J Am Soc Nephrol 2015; 10: 1553-1559 doi:10.2215/CJN.11391114
    CrossrefPubMedGoogle Scholar
  • 16 Williamson JD, Supiano MA, Applegate WB. et al. SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial. JAMA 2016; 315: 2673-2682 doi:10.1001/jama.2016.7050
    CrossrefPubMedGoogle Scholar
  • 17 Cheng LT, Gao YL, Gu Y. et al. Stepwise increase in the prevalence of isolated systolic hypertension with the stages of chronic kidney disease. Nephrol Dial Transplant 2008; 23: 3895-3900 doi:10.1093/ndt/gfn383
    CrossrefPubMedGoogle Scholar
  • 18 Bavishi C, Goel S, Messerli FH. Isolated Systolic Hypertension: An Update After SPRINT. 2016; 129: 1251-1258 doi:10.1016/j.amjmed.2016.08.032
    PubMedGoogle Scholar